GSK Pharma Q2 Review- Temporary Hiccups Lead To Muted Show On A YoY Basis; Motilal Oswal Maintains Neutral

3 days ago 6

ARTICLE AD BOX

GSK Pharma's current valuation already reflects the potential upside, hence Motilal Oswal reiterates Neutral stance on the stock.

07 Nov 2025, 11:28 AM IST i

07 Nov 2025, 11:28 AM IST

07 Nov 2025, 11:28 AM IST

31.4%) due to steady other expenses costs and a cut in employee costs on a YoY basi</p><p>(Photo: GSK Pharma website). </p></div>

GSK Pharma's EBITDA margin expanded 250bp YoY to 34.3% (our est: 31.4%) due to steady other expenses costs and a cut in employee costs on a YoY basi

(Photo: GSK Pharma website).

In addition to vaccines, GSK Pharma is building a specialty portfolio in the respiratory and oncology segments. Products launched in the oncology segment have also been well-received by healthcare professionals.

To continue reading this story

You must be an existing Premium User

Already a Premium User?

Read Entire Article